June 16, 2011
The Oregon Bioscience Association is pleased to share industry updates, benchmarks, strategy and milestones in its 2010 Annual Report on Community, Collaboration and Commercialization. Throughout 2010, Oregon’s bioscience industry remained an economic bright spot. Despite this less than ideal environment, Oregon Bio made steady, measurable progress in building a solid financial foundation for future growth. […]
June 16, 2011
Oregon’s bioscience industry is recognized for its contributions to the health and well-being of our people, and there is a growing awareness of its positive impact on our state’s economy and on each community in which bioscience companies and institutions operate. Read More
June 15, 2011
The Therapeutic Interchange Program (TIP) has developed a process allowing physicians and other prescribers to endorse the Washington State Preferred Drug List (PDL), and requires pharmacists to automatically substitute the preferred drug for non preferred drugs prescribed by these practitioners unless the prescription is for a refill of an antipsychotic, antidepressant, chemotherapy, antiretroviral, or immunosuppressive […]
June 15, 2011
This section contains the department’s rules for the endorsing practitioner therapeutic interchange program (TIP). TIP is established under RCW. The statutes require state-operated prescription drug programs to allow physicians and other prescribers to endorse a Washington preferred drug list (PDL) and, in most cases, requires pharmacists to automatically substitute a preferred, equivalent drug from the […]
June 14, 2011
By Brian Gormley Wall Street Journal U.S. pharmaceutical companies have long lived with generic rivals, and soon biotechnology concerns will face similar competition. Through the health-care reform law passed last year, Congress created a regulatory path for companies to introduce “biosimilars,” or nearly exact copies of biological drugs that have come off patent. Read More
May 20, 2011
By Jorgo Chatzimarkakis, PhD, member of European Parliament The Health Care Blog Around the world and now in the United States, there is a broadening discussion of how best to proceed down the path of approving and getting to market medicines called biosimilars. Biosimilars are non-identical copies of next generation medicines known as biologics. As […]
May 19, 2011
By Andre Williams, Association of Black Cardiologists Politic365.com President Barack Obama recently indicated his interest in improving the Food and Drug Administration’s (FDA) approval process for new medical devices, saying the agency could “keep patients safer while getting innovative and life-saving products to market faster.” Read More
April 24, 2011
Dr. Marcy L. Zwelling-Aamot Sacramento Bee When it comes to biologics, is biosimilar good enough? There is a new development in pharmaceuticals. It is a class of drugs called biologics. They are not only new; they are each unique. Read More
April 14, 2011
William P. Bro, Kidney Cancer Association At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney […]
April 14, 2011
Tom Blackwell, National Post A growing tide of high-priced specialty medicines for arthritis, cancer and other diseases is set to put unprecedented pressure on workplace drug plans, likely forcing strict limits on what they cover, higher employee premiums and even an end to some plans altogether, experts are warning. Read more
